Advertisement

Topics

FDA panel votes against approval of J&J arthritis drug

11:38 EDT 2 Aug 2017 | Reuters

(Reuters) - The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks and it should not be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

Original Article: FDA panel votes against approval of J&J arthritis drug

NEXT ARTICLE

More From BioPortfolio on "FDA panel votes against approval of J&J arthritis drug"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...